W L Joseph|D L Morton - JoVE Visualize

Showing results (121-130 of 370) with videos related to

Pageof 37

Sort By:

Journal of Clinical & Laboratory Immunology|November 1, 1980

Natural humoral immunity in patients with malignant diseaseM Higuchi, R K Gupta, R F Irie, et al.

Annals of Surgical Oncology|April 13, 2000

Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?P Shen, J M Guenther, L A Wanek, et al.

Journal of the American College of Surgeons|September 3, 1999

Lymphatic mapping and sentinel lymphadenectomy after wide local excision of primary melanomaP R Kelemen, R Essner, L J Foshag, et al.

Cancer Immunology, Immunotherapy : CII|January 1, 1992

Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigenK K Hunt, M Shibata, R K Gupta, et al.

Cancer|March 1, 1979

Internal hemipelvectomy--excision of the hemipelvis with limb preservation. An alternative to hemipelvectomyF R Eilber, T T Grant, D Sakai, et al.

Seminars in Surgical Oncology|May 20, 1998

Overview of melanoma vaccines: active specific immunotherapy for melanoma patientsD W Ollila, M C Kelley, G Gammon, et al.

Oncology (Williston Park, N.Y.)|December 3, 1999

Vaccine therapy for patients with melanomaP I Haigh, L A Difronzo, G Gammon, et al.

Tissue Antigens|March 1, 1978

A new heterophile antigen: man distinguished from higher apes and other mammalsR F Irie, K Irie, E J Shaw, et al.

Cancer|June 15, 1991

Ganglioside GM3:GD3 ratio as an index for the management of melanomaM H Ravindranath, T Tsuchida, D L Morton, et al.

Cellular Immunology|June 15, 1997

Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patientsT Takahashi, R F Irie, D L Morton, et al.

Pageof 37

Showing results (121-130 of 370) with videos related to

Sort By:

Pageof 37

Journal of Clinical & Laboratory Immunology|November 1, 1980

Natural humoral immunity in patients with malignant diseaseM Higuchi, R K Gupta, R F Irie, et al.

Annals of Surgical Oncology|April 13, 2000

Can elective lymph node dissection decrease the frequency and mortality rate of late melanoma recurrences?P Shen, J M Guenther, L A Wanek, et al.

Journal of the American College of Surgeons|September 3, 1999

Lymphatic mapping and sentinel lymphadenectomy after wide local excision of primary melanomaP R Kelemen, R Essner, L J Foshag, et al.

Cancer Immunology, Immunotherapy : CII|January 1, 1992

Complement-dependent lysis of tumor cells by a baboon IgM antibody to a tumor-associated antigenK K Hunt, M Shibata, R K Gupta, et al.

Cancer|March 1, 1979

Internal hemipelvectomy--excision of the hemipelvis with limb preservation. An alternative to hemipelvectomyF R Eilber, T T Grant, D Sakai, et al.

Seminars in Surgical Oncology|May 20, 1998

Overview of melanoma vaccines: active specific immunotherapy for melanoma patientsD W Ollila, M C Kelley, G Gammon, et al.

Oncology (Williston Park, N.Y.)|December 3, 1999

Vaccine therapy for patients with melanomaP I Haigh, L A Difronzo, G Gammon, et al.

Tissue Antigens|March 1, 1978

A new heterophile antigen: man distinguished from higher apes and other mammalsR F Irie, K Irie, E J Shaw, et al.

Cancer|June 15, 1991

Ganglioside GM3:GD3 ratio as an index for the management of melanomaM H Ravindranath, T Tsuchida, D L Morton, et al.

Cellular Immunology|June 15, 1997

Recognition of gp43 tumor-associated antigen peptide by both HLA-A2 restricted CTL lines and antibodies from melanoma patientsT Takahashi, R F Irie, D L Morton, et al.

Pageof 37